Dong Zhang1,#, Lingxia Tong2,#, Qingjun Wang1, Yunfeng Cao3, Yu Gao1, Donghua Yang1, Tianhao Bao4,5, Zhitu Zhu1,*
Oncologie, Vol.22, No.2, pp. 75-82, 2020, DOI:10.32604/oncologie.2020.012376
Abstract Predicting the onset and metastasis of early tumor is the primary
means of improving lung cancer prognosis. The purpose of this study was to
identify the ability of plasma metabolomics combined with blood markers to
establish benign lung disease versus lung cancer regression models. Blood
samples were collected from 174 lung cancer patients, 350 benign lung disease
patients and 100 healthy volunteers and the metabolites were analyzed by mass
spectrometry. The target metabolites consisted of 23 amino acids, 26
acylcarnitines and 45 conventional blood markers. A regression analysis model
was established based on 12 metabolites… More >
Login
Register
